Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 11, 2014, Pages 1903-1911

  Li, Furong ^a   Zheng, Chunxia ^a   Zhong, Yongzhong ^a   Zeng, Caihong ^a   Xu, Feng ^a   Yin, Ru ^a   Jiang, Qi ^a   Zhou, Minlin ^a   Liu, Zhihong ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID; UROKINASE RECEPTOR; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; PREDNISONE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOCAL GLOMERULOSCLEROSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MINIMAL CHANGE DISEASE; PROTEIN BLOOD LEVEL; ADOLESCENT; AREA UNDER THE CURVE; BLOOD; FOLLOW UP; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; LIPOID NEPHROSIS; MIDDLE AGED; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; AREA UNDER CURVE; BIOMARKERS; FEMALE; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; MALE; MIDDLE AGED; NEPHROSIS, LIPOID; PREDICTIVE VALUE OF TESTS; PREDNISONE; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; ROC CURVE; YOUNG ADULT;

EID: 84923853644     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02370314     Document Type: Article

References (40)

1. D’Agati VD, Kaskel FJ, Falk RJ: Focal segmental glomerulosclerosis. N Engl J Med 365: 2398–2411, 2011
2. Zhang S, Audard V, Fan Q, Pawlak A, Lang P, Sahali D: Immunopathogenesis of idiopathic nephrotic syndrome. Contrib Nephrol 169: 94–106, 2011
3. Sharma M, Sharma R, McCarthy ET, Savin VJ: The focal segmental glomerulosclerosis permeability factor: Biochemical characteristics and biological effects. Exp Biol Med (Maywood) 229: 85–98, 2004
4. Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, Lovell H, Warady B, Gunwar S, Chonko AM, Artero M, Vincenti F: Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 334: 878–883, 1996
5. Gbadegesin R, Lavin P, Foreman J, Winn M: Pathogenesis and therapy of focal segmental glomerulosclerosis: An update. Pediatr Nephrol 26: 1001–1015, 2011
6. McCarthy ET, Sharma M, Savin VJ: Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 5: 2115–2121, 2010
7. Yap HK, Cheung W, Murugasu B, Sim SK, Seah CC, Jordan SC: Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: Evidence for increased IL-13 mRNA expression in relapse. J Am Soc Nephrol 10: 529–537, 1999
8. Tain YL, Chen TY, Yang KD: Implications of serum TNF-beta and IL-13 in the treatment response of childhood nephrotic syndrome. Cytokine 21: 155–159, 2003
9. Mauer SM, Hellerstein S, Cohn RA, Sibley RK, Vernier RL: Recurrence of steroid-responsive nephrotic syndrome after renal transplantation. J Pediatr 95: 261–264, 1979
10. Rea R, Smith C, Sandhu K, Kwan J, Tomson C: Successful transplant of a kidney with focal segmental glomerulosclerosis. Nephrol Dial Transplant 16: 416–417, 2001
11. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J: Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17: 952–960, 2011
12. Wei C, Möller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Mundel P, Reiser J: Modification of kidney barrier function by the urokinase receptor. Nat Med 14: 55–63, 2008
13. Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, McMahan JL, Radeva M, Heil KM, Trautmann A, Anarat A, Emre S, Ghiggeri GM, Ozaltin F, Haffner D, Gipson DS, Kaskel F, Fischer DC, Schaefer F, Reiser J; PodoNet and FSGS CT Study Consortia: Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 23: 2051–2059, 2012
14. Huang J, Liu G, Zhang YM, Cui Z, Wang F, Liu XJ, Chu R, Chen Y, Zhao MH: Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. Kidney Int 84: 366–372, 2013
15. Meijers B, Maas RJ, Sprangers B, Claes K, Poesen R, Bammens B, Naesens M, Deegens JK, Dietrich R, Storr M, Wetzels JF, Evenepoel P, Kuypers D: The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int 85: 636–640, 2014
16. Wada T, Nangaku M, Maruyama S, Imai E, Shoji K, Kato S, Endo T, Muso E, Kamata K, Yokoyama H, Fujimoto K, Obata Y, Nishino T, Kato H, Uchida S, Sasatomi Y, Saito T, Matsuo S: Amulticenter crosssectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease. Kidney Int 85: 641–648, 2014
17. Braun N, Schmutzler F, Lange C, Perna A, Remuzzi G, Risler T, Willis NS: Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. Cochrane Database Syst Rev 16: CD003233, 2008
18. Gipson DS, Trachtman H, Kaskel FJ, Radeva MK, Gassman J, Greene TH, Moxey-Mims MM, Hogg RJ, Watkins SL, Fine RN, Middleton JP, Vehaskari VM, Hogan SL, Vento S, Flynn PA, Powell LM, McMahan JL, Siegel N, Friedman AL: Clinical trials treating focal segmental glomerulosclerosis shouldmeasure patient quality of life. Kidney Int 79: 678–685, 2011
19. Banfi G, Moriggi M, Sabadini E, Fellin G, D’Amico G, Ponticelli C: The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol 36: 53–59, 1991
20. Stirling CM, Mathieson P, Boulton-Jones JM, Feehally J, Jayne D, Murray HM, Adu D: Treatment and outcome of adult patients with primary focal segmental glomerulosclerosis in five UK renal units. QJM 98: 443–449, 2005
21. Korbet SM: Treatment of primary FSGS in adults. J Am Soc Nephrol 23: 1769–1776, 2012
22. Radhakrishnan J, Cattran DC: The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines—application to the individual patient. Kidney Int 82: 840–856, 2012
23. Koukoulaki M, Goumenos DS: The accumulated experience with the use of mycophenolate mofetil in primary glomerulonephritis. Expert Opin Investig Drugs 19: 673–687, 2010
24. Dimkovic N, Jovanovic D, Kovacevic Z, Rabrenovic V, Nesic V, Savin M, Mitic B, Ratkovic M, Curic S, Mitic I, Pljesa S, Perunicic- Pekovic G, Marinkovic J, Popovic J, Vujic D: Mycophenolate mofetil in high-risk patients with primary glomerulonephritis: results of a 1-year prospective study. Nephron Clin Pract 111: c189–c196, 2009
25. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC, Toronto Glomerulonephritis Registry G; Toronto Glomerulonephritis Registry Group: Focal and segmental glomerulosclerosis: Definition and relevance of a partial remission. J AmSoc Nephrol 16: 1061–1068, 2005
26. Tang X, Xu F, Chen DM, Zeng CH, Liu ZH: The clinical course and long-term outcome of primary focal segmental glomerulosclerosis in Chinese adults. Clin Nephrol 80: 130–139, 2013
27. D’Agati VD, Fogo AB, Bruijn JA, Jennette JC: Pathologic classification of focal segmental glomerulosclerosis: A working proposal. Am J Kidney Dis 43: 368–382, 2004
28. Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G, D’Agati V, Appel G: Adult minimal-change disease: Clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2: 445–453, 2007
29. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A: A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58: 259–263, 1976
30. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604–612, 2009
31. Kirkwood BR, Sterne JAC: Essential Medical Statistics, 2nd Ed., Oxford, UK, Blackwell Science Publications, 2003
32. Bock ME, Price HE, Gallon L, Langman CB: Serum soluble urokinase type plasminogen activator receptor levels and idiopathic FSGS in children: A single-center report. Clin J AmSoc Nephrol 8: 1304–1311, 2013
33. Franco Palacios CR, Lieske JC, Wadei HM, Rule AD, Fervenza FC, Voskoboev N, Garovic VD, Zand L, Stegall MD, Cosio FG, Amer H: Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation 96: 394–399, 2013
34. Thomas DB, Franceschini N, Hogan SL, Ten Holder S, Jennette CE, Falk RJ, Jennette JC: Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int 69: 920–926, 2006
35. Malhotra KP, Prasad N, Jain M: Morphological features and prognostic significance of tip variant of focal segmental glomerulosclerosis: Study of an Indian cohort. Indian J Pathol Microbiol 53: 248–252, 2010
36. Shalhoub RJ: Pathogenesis of lipoid nephrosis: A disorder of Tcell function. Lancet 2: 556–560, 1974
37. Koyama A, Fujisaki M, Kobayashi M, Igarashi M, Narita M: A glomerular permeability factor produced by human T cell hybridomas. Kidney Int 40: 453–460, 1991
38. Ding WY, Koziell A, McCarthy HJ, Bierzynska A, Bhagavatula MK, Dudley JA, Inward CD, Coward RJ, Tizard J, Reid C, Antignac C, Boyer O, Saleem MA: Initial steroid sensitivity in children with steroid-resistant nephrotic syndrome predicts post-transplant recurrence. J Am Soc Nephrol 25: 1342–1348, 2014
39. Meyrier A: Focal and segmental glomerulosclerosis: Multiple pathways are involved. Semin Nephrol 31: 326–332, 2011
40. Sever S, Trachtman H, Wei C, Reiser J: Is there clinical value in measuring suPAR levels in FSGS? Clin J AmSoc Nephrol 8: 1273–1275, 2013